



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 18, 2020

Via E-mail

Chris Frankenfield
Vice President, Corporate Legal Affairs
Blueprint Medicines Corporation
45 Sidney Street
Cambridge, Massachusetts 02139

Re: Blueprint Medicines Corporation
Form 10-Q for the quarterly period ended September 30, 2019
Exhibit No. 10.1 - License Agreement, effective October 15, 2019, by and between
Blueprint Medicines Corporation and Clementia Pharmaceuticals, Inc.
Exhibit 10.2 - Sixth Amendment to Collaboration and License Agreement, effective
November 1, 2019, by and among F. Hoffmann-La Roche Ltd, Hoffmann-La Roche
Inc. and Blueprint Medicines Corporation
Filed November 5, 2019
File No. 001-37359

Dear Mr. Frankenfield:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance